Conaghan PG, Bowes MA, Kingsbury SR, et al. - Researchers conducted 26-week randomized, double-blind, placebo-controlled phase 2a study with a 26-week open-label safety extension substudy in six European sites in order to assess the effectiveness, safety, and tolerability of MIV-711 (a novel selective cathepsin K inhibitor with advantageous impacys on bone and cartilage in preclinical osteoarthritis models) in individuals (n = 244) with symptomatic, radiographic knee osteoarthritis, Kellgren–Lawrence grade 2 or 3, and pain score of 4 to 10 on a numerical rating scale. Results suggest that for pain, MIV-711 was not more efficient compared with placebo. However, it notably decreased bone and cartilage progression with a reassuring safety profile.